ObjectiveTo investigate the correlation between different female body mass index （BMI） values and key indicators of in vitro fertilization/intracytoplasmic sperm injection （IVF/ICSI） treatment cycles， as well as their impact on obstetric outcomes. MethodsA retrospective analysis was conducted on data from patients who underwent IVF/ICSI treatment， with 19 834 cycles included after propensity score matching to balance group differences. Based on the Chinese BMI classification standards with extended categories， patients were stratified into five groups： severely underweight （BMI<16）， underweight （16.0≤BMI<18.5）， normal weight （18.5≤BMI<24.0）， overweight （24.0≤BMI<28.0）， and obese （BMI≥28.0）. Baseline characteristics， ovarian stimulation protocols， treatment processes， and assisted reproductive outcomes were compared among the groups. Additionally， 75 delivered patients with complications were followed up to analyze the association between BMI and pregnancy-related complications. ResultsNo statistically significant differences were observed among the five groups in baseline parameters such as age， duration of infertility， or antral follicle count. Regarding ovarian stimulation protocols and processes， a statistically significant difference was found in the number of IVF oocytes retrieved （P<0.001）， with the normal-weight group showing a significantly higher number than both the overweight and obese groups. In terms of assisted reproductive outcomes， no significant differences were observed in biochemical pregnancy rates or birth defect rates. However， cumulative live birth rates differed significantly among the groups （P<0.05）， which was significantly higher in the overweight group than in the normal-weight group. Among the 75 followed-up patients， 25 were diagnosed with gestational hypertension， and 22 with gestational diabetes mellitus， of whom overweight and obese individuals accounted for 60.00% and 45.40% of the respective complications. ConclusionFemale BMI is significantly associated with IVF/ICSI outcomes. Pre-pregnancy body mass evaluation should be emphasized in patients with extremely low body weight. Although the live birth rate of overweight and obese patients was comparable to that of the normal-weight group， weight reduction prior to treatment is strongly recommended to minimize risks of miscarriage， preterm birth， and pregnancy complications.

Objective:To evaluate the efficacy and safety of radiotherapy as a combined mode with in-situ vaccine for patients with advanced soft tissue sarcoma(STS).Methods:The clinical data of 12 patients with advanced STS who received combination therapy mode at the Cancer Center of Gulou Hospital Affiliated to the School of Medicine of Nanjing University between December 2020 and September 2024 were retrospectively analyzed.All 12 patients received combined therapy.The main radiotherapeutic approach was hypofractionated radiotherapy.The targeted therapy mainly involved Anlotinib(in 10 cases)or Apatinib(in 2 cases).Immunotherapy mainly involved PD-1 antibodies.The primary endpoint was disease control rate(DCR),and the secondary endpoints were objective response rate(ORR)and safety.Results:Among the 12 STS patients who received combined treatment,0 cases achieved CR,4 cases achieved PR;7 cases had SD,and 1 case had PD.The ORR was 33%,and the DCR was 91.7%,among which the DCR of the target lesions was 100%.Among the 12 patients,9 patients experienced grade Ⅰ to grade Ⅱ adverse reactions.The most frequently occurring hematological adverse reactions were anemia(6 cases)and abnormal results of liver function tests(3 cases).The most frequently occurring non-hematological adverse reactions were proteinuria(5 cases),hypertension(4 cases),abnormal thyroid function(3 cases),anorexia(3 cases),and nausea and vomiting(2 cases).Only 2 cases had grade Ⅲ hematological toxicity,and 1 case had grade Ⅲpneumothorax.Conclusion:Radiotherapy as a combined therapy mode with in situ vaccine can achieve a higher DCR in advanced soft tissue sarcomas without serious adverse reactions.This combined treatment modality demonstrates good efficacy and safety.

Objective : To analyze the data related to the clinical outcome of preimplantation genetic testing (PGT) for double frozen , double biopsied blastocysts and double frozen , once biopsied blastocysts , in order to expand the existing data and provide some guidance for the clinical value and safety of PGT for frozen⁃thawed embryos . Methods : Retrospective analysis was made on the 38 PGT cycles of frozen⁃thawed blastocysts . According to the frequency of biopsy , cases in the study were divided into two groups : double frozen , double biopsy ( DFDB) group and double frozen , single biopsy ( DFSB) group . The freezing method was vitrification . Results : There were 24 patients in DFDB group , 34 blastocysts were not diagnosed in the last PGT cycle , 32 blastocysts survived after thawing , and the survival rate of thawed blastocysts was 94. 12% . After the second biopsy of these 32 blastocysts , genetic testing was performed , and all of them were definitely diagnosed , including 15 normal blastocysts (46. 88% ) and 17 abnormal blastocysts (53 . 13% ) . There were 14 patients in DFSB . The remaining 50 blastocysts in the last ICSI cycle were thawed and all blastocysts survived after thawing . Biopsy of these 50 blastocysts and genetic analysis showed that 47 blastocysts were diagnosed , including 9 normal blastocysts (18 . 00% ) , 28 abnormal blastocysts (56. 00% ) , 10 mosaic blastocysts (20. 00% ) , and 3 undiagnosed blastocysts (6. 00% ) . In DFDB group and DFSB group , 8 patients and 5 patients transferred the normal blastocystswhich all survivedafter thawing . There were 5 clinical pregnancies and 3 clinical pregnancies , respectively . One healthy live birth was obtained respectively in each group . Conclusion Acceptable pregnancy rate can be obtained whatever DFSB or DFDB blastocyst , which is of clinical value . However , due to the small sample size , we need to expand the sample size to further explore its safety .

Preimplantation genetic testing (PGT) has been widely used today in assisted reproductive technology (ART). PGT can detect embryonic monogenic genetic diseases, chromosome structure and number abnormalities, and improve clinical outcomes in terms of embryo implantation, clinical pregnancy, and live birth rates. Biopsy procedure in PGT is 'invasive' for embryos and has high requirement for equipment and operators. With the discovery of free DNA for gene analysis in blastocyst fluid and embryo culture fluid and embryo culture fluid, a noninvasive PGT (NiPGT) becomes a potential alternative method. It has a broad application prospect in the field of assisted reproduction. Now we summarize the current application and research progress of NiPGT and analyze its effectiveness and limitations, to provide a basis for clinical applications.

Preimplantation genetic testing (PGT) has been widely used today in assisted reproductive technology (ART). PGT can detect embryonic monogenic genetic diseases, chromosome structure and number abnormalities, and improve clinical outcomes in terms of embryo implantation, clinical pregnancy, and live birth rates. Biopsy procedure in PGT is 'invasive' for embryos and has high requirement for equipment and operators. With the discovery of free DNA for gene analysis in blastocyst fluid and embryo culture fluid and embryo culture fluid, a noninvasive PGT (NiPGT) becomes a potential alternative method. It has a broad application prospect in the field of assisted reproduction. Now we summarize the current application and research progress of NiPGT and analyze its effectiveness and limitations, to provide a basis for clinical applications.